DOAC Dosing Options in Anticoagulation Prophylaxis for Cancer Outpatients

05 Feb 20264 min read0 viewsINTERVENTIONAL Trial

GIST

Official title: A Comparison of Anticoagulant Dosing Strategies to Reduce VTE and Mortality in Cancer Outpatients: A Randomized, Pragmatic Trial Summary: Blood clots, also known as venous thromboembolism (VTE), are a common and serious complication for people with cancer. They can lead to pain, hospitalizations, delayed cancer treatment, and even death.

Although national guidelines recommend using blood thinners (anticoagulants) to prevent clots in cancer patients who are at higher risk, these medications are not commonly prescribed due to concerns about bleeding and inconvenience. This study will test different ways of using a commonly prescribed blood thinner called apixaban (brand name Eliquis) to see if it can safely and effectively reduce the risk of blood clots and death in cancer patients who are at moderate risk for VTE.

The study focuses on people who have a "Khorana score" of 2, which puts them at intermediate risk for developing blood clots. The study will include approximately 996 participants with solid tumors or lymphoma who are starting or recently started cancer-directed therapy.

Clinical Editorial

Strategic aims and study design in cancer-associated VTE prevention

Inclusion is tied to a Khorana score of 2, indicating intermediate risk for clot formation.

Treatments are administered for a 6-month period.

The sponsor does not supply the study drug; instead, apixaban will be prescribed and dispensed through usual care channels, with decisions on continuation after the study left to participants and their clinicians.

Purpose and scope: A pragmatic, randomized trial evaluates dosing strategies of apixaban to reduce venous thromboembolism (VTE) and mortality risk in cancer outpatients at intermediate VTE risk.
Population and eligibility: Approximately 996 participants with solid tumors or lymphoma are initiating or recently starting cancer-directed therapy.
Intervention arms and comparator: Participants are allocated to one of three groups:
Group 1: Apixaban 2.5 mg taken twice daily (standard prophylactic dosing).
Group 2: Apixaban 5 mg taken once daily (alternative, more convenient dosage).
Group 3: No anticoagulant therapy (standard care).
Study design characteristics: The trial is described as pragmatic, aiming to resemble routine clinical practice with minimal procedural burden.

Key outcomes and objectives

Primary questions: The study seeks to determine whether a once-daily apixaban regimen provides comparable protection against VTE and mortality relative to the standard twice-daily prophylaxis, and whether either apixaban dosing strategy offers advantages over no preventive anticoagulation.
Outcomes tracked: Incidence of VTE events, major or serious bleeding events, and all-cause mortality during the 6-month follow-up.

Context and potential implications

The trial directly compares dosing paradigms to inform feasibility and safety of broader prophylaxis use.

Rationale: While guidelines endorse anticoagulant prophylaxis for select cancer patients at elevated risk, uptake remains limited due to bleeding concerns and practical considerations.
Practical relevance: If the once-daily dosing proves noninferior to the twice-daily approach and both outperform no anticoagulation, clinicians might adopt a simpler regimen to enhance adherence and real-world effectiveness in intermediate-risk populations.

Status and timeline

Enrollment and status: The study is currently recruiting, with an estimated enrollment of 996 participants.
Milestones: Completion is projected for August 2035, reflecting a long-term follow-up horizon typical of pragmatic cancer prevention trials.

Limitations and reporting cautions

Explicit limitations are not detailed in the provided content; however, as with pragmatic designs, generalizability may depend on how closely participating sites mirror routine practice, and the open-channel drug provision may influence adherence and real-world applicability.

Uncertainty and gaps

It also notes that the study drug is not sponsor-provided, but filled through standard care pathways, a factor that may affect adherence and comparability across sites.

The source does not provide granular data on demographic subgroups, tumor types, prior thrombosis history, or precise safety signals beyond the general outcome intentions.